Literature DB >> 34966452

GPNMB overexpression is associated with extensive bone metastasis and poor prognosis in renal cell carcinoma.

Jian-Po Zhai1, Zhen-Hua Liu1, Hai-Dong Wang1, Guang-Lin Huang1, Li-Bo Man1.   

Abstract

Glycoprotein non-metastatic protein B (GPNMB) promotes bone metastasis (BM) in various types of cancer. However, GPNMB expression and its function in patients with renal cell carcinoma (RCC) and BM is still unknown. Therefore, the clinical significance of GPNMB and its biological function in RCC with BM was investigated in the present study. A total of 31 patients with RCC and BM were retrospectively collected. The association between GPNMB protein expression level on the primary tumor and the clinicopathological characteristics of the patients was analyzed. Kaplan-Meier analysis was used to investigate the association between GPNMB expression and the prognosis of the patients. The effects of GPNMB inhibition on cell proliferation, migration and invasion in RCC cells were investigated using short hairpin (sh)RNA. High GPNMB expression level was significantly associated with the number (P=0.001) and the extent of BM (P=0.001), Fuhrman grade (P=0.037), and ERK expression level (P=0.003) of the primary tumor. In addition, GPNMB overexpression was significantly associated with poor prognosis with respect to overall survival time (P=0.001). Furthermore, a specific shRNA sequence targeting the GPNMB gene was constructed and transduced into the ACHN cell line, using a lentivirus vector to obtain a stable cell line with low mRNA expression level of GPNMB. Low GPNMB expression level inhibited RCC cell proliferation, which was measured using a Cell Counting Kit-8 assay. Cell migration and invasion ability was significantly decreased in GPNMB knockdown RCC cells compared with that in cells transduced with the negative control shRNA. In addition, the protein expression levels of phosphorylated ERK were lower in the GPNMB shRNA-transduced ACHN cells compared with those in the control cells. Therefore, these results suggested that GPNMB plays an important role in tumor progression in RCC with BM. Furthermore, it might serve as a predictive marker for BM and as a poor prognostic factor in RCC with BM. GPNMB downregulation suppressed the proliferation, migration and invasion of the RCC cells, which may be mediated through the inhibition of the ERK signaling pathway.
Copyright © 2021, Spandidos Publications.

Entities:  

Keywords:  ERK; GPNMB; RCC; bone metastasis; prognosis

Year:  2021        PMID: 34966452      PMCID: PMC8669674          DOI: 10.3892/ol.2021.13154

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Authors:  Shreyas S Joshi; Elizabeth A Handorf; Matthew Zibelman; Elizabeth R Plimack; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone; Daniel M Geynisman
Journal:  Eur Urol       Date:  2018-06-05       Impact factor: 20.096

2.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Authors:  Johanna Bendell; Mansoor Saleh; April A N Rose; Peter M Siegel; Lowell Hart; Surendra Sirpal; Suzanne Jones; Jennifer Green; Elizabeth Crowley; Ronit Simantov; Tibor Keler; Thomas Davis; Linda Vahdat
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

4.  Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na+/K+-ATPase.

Authors:  Yoko Ono; Shinsuke Chiba; Hirohito Yano; Noriyuki Nakayama; Masanao Saio; Kazuhiro Tsuruma; Masamitsu Shimazawa; Toru Iwama; Hideaki Hara
Journal:  Biochem Biophys Res Commun       Date:  2016-11-09       Impact factor: 3.575

Review 5.  Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Authors:  April A N Rose; Marco Biondini; Rafael Curiel; Peter M Siegel
Journal:  Pharmacol Ther       Date:  2017-05-22       Impact factor: 12.310

6.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

Authors:  M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz
Journal:  Ann Oncol       Date:  2011-09-02       Impact factor: 32.976

Review 7.  A multidisciplinary approach for the management of earlier stage renal cell carcinoma.

Authors:  Ana M Molina
Journal:  Urol Oncol       Date:  2018-01       Impact factor: 3.498

Review 8.  Epidemiology of Renal Cell Carcinoma.

Authors:  Umberto Capitanio; Karim Bensalah; Axel Bex; Stephen A Boorjian; Freddie Bray; Jonathan Coleman; John L Gore; Maxine Sun; Christopher Wood; Paul Russo
Journal:  Eur Urol       Date:  2018-09-19       Impact factor: 20.096

9.  MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Authors:  April A N Rose; Matthew G Annis; Dennie T Frederick; Marco Biondini; Zhifeng Dong; Lawrence Kwong; Lynda Chin; Tibor Keler; Thomas Hawthorne; Ian R Watson; Keith T Flaherty; Peter M Siegel
Journal:  Clin Cancer Res       Date:  2016-08-11       Impact factor: 12.531

10.  Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.

Authors:  Chen Chen; Yukari Okita; Yukihide Watanabe; Fumie Abe; Muhammad Ali Fikry; Yumu Ichikawa; Hiroyuki Suzuki; Akira Shibuya; Mitsuyasu Kato
Journal:  Cancer Res       Date:  2018-09-17       Impact factor: 12.701

View more
  1 in total

1.  GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma-Their Roles in Cancer Stemness, Therapy Resistance, and Metastasis.

Authors:  Yohei Kawasaki; Hitomi Suzuki; Shinsuke Suzuki; Takechiyo Yamada; Maya Suzuki; Ayumi Ito; Haruka Hatakeyama; Masahito Miura; Yasufumi Omori
Journal:  Pathol Oncol Res       Date:  2022-08-19       Impact factor: 2.874

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.